ancer hemotherapyand harmacolo
Cancer Chemother Pharmacol (1990) 2 6 : 7 1 - 7 4
© Springer-Verlag 1990
Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide H. Andersonl, M. J. Lind 1, N. Thatcher 1, z, R. Swindell3, A. Woodcock 2, and K. B. Carroll2 i CRC Department Medical Oncology, Christie Hospital, Manchester 2 Department Thoracic Medicine, Wythenshawe Hospital, Manchester 3 Department Medical Statistics, Christie Hospital, Manchester Received 11 May 1989/Accepted 12 October 1989
Summary. A total of 47 poor-risk small-cell lung cancer patients (elderly, poor performance status, recent myocardial infarction, or extensive-stage disease with biochemical abnormalities) were treated with a regimen of bolus ifosfamide at 1.5 g/m 2 with equidose mesna as a 30-min infusion, followed by 100 mg oral etoposide daily for 8 days. Therapy was repeated every 3 weeks. The overall response rate was 60% (75% for limited-stage and 48% for extensive-stage disease), and the overall median survival was 7 months. Patients' performance status significantly improved with therapy (P
Cancer Chemother Pharmacol (1990) 2 6 : 7 1 - 7 4
© Springer-Verlag 1990
Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide H. Andersonl, M. J. Lind 1, N. Thatcher 1, z, R. Swindell3, A. Woodcock 2, and K. B. Carroll2 i CRC Department Medical Oncology, Christie Hospital, Manchester 2 Department Thoracic Medicine, Wythenshawe Hospital, Manchester 3 Department Medical Statistics, Christie Hospital, Manchester Received 11 May 1989/Accepted 12 October 1989
Summary. A total of 47 poor-risk small-cell lung cancer patients (elderly, poor performance status, recent myocardial infarction, or extensive-stage disease with biochemical abnormalities) were treated with a regimen of bolus ifosfamide at 1.5 g/m 2 with equidose mesna as a 30-min infusion, followed by 100 mg oral etoposide daily for 8 days. Therapy was repeated every 3 weeks. The overall response rate was 60% (75% for limited-stage and 48% for extensive-stage disease), and the overall median survival was 7 months. Patients' performance status significantly improved with therapy (P
